TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
22 mai 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA...
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
27 avr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to...
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
26 avr. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to...
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
14 avr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using...
TransCode Therapeutics to present at AACR Annual Meeting 2023
06 avr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
05 avr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
04 avr. 2023 21h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today...
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
03 avr. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports 2022 Results; Provides Business Update
31 mars 2023 16h01 HE
|
TransCode Therapeutics, Inc.
BOSTON, March 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial...
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
28 févr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, announced...